DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on May 19, 2008; DOI: 10.1124/dmd.107.018663


This Article
Right arrow Full Text (PDF)
Right arrow Erratum
Right arrow All Versions of this Article:
dmd.107.018663v1
36/8/1698    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fahmi, O. A.
Right arrow Articles by Nettleton, D. O
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fahmi, O. A.
Right arrow Articles by Nettleton, D. O


Received for publication September 4, 2007.
Revised May 15, 2008.
Accepted for publication May 16, 2008.

A COMBINED MODEL FOR PREDICTING CYP3A4 CLINICAL NET DRUG-DRUG INTERACTION BASED ON CYP3A4 INHIBITION, INACTIVATION, AND INDUCTION DETERMINED IN VITRO

Odette A. Fahmi 1*, Tristan Scott Maurer 2, Mary Kish 2, Edwin Cardenas 3, Sherri Boldt 4, David O Nettleton 1

1 Pfizer 2 Pfizer Inc. 3 University of Connecticut, Storrs, CT 4 Pfizer, Inc.

* Address correspondence to: E-mail: odette.a.fahmi{at}pfizer.com

Abstract

Although approaches to the prediction of DDIs arising via time-dependent inactivation have recently been developed, such approaches do not account for simple competitive inhibition or induction. Accordingly, these approaches do not provide accurate predictions of DDIs arising from simple competitive inhibition (e.g. ketoconazole) or induction of P450s (e.g. phenytoin). In addition, methods which focus upon a single interaction mechanism are likely to yield misleading predictions in the face of mixed mechanisms (e.g. ritonavir). As such, we have developed a more comprehensive mathematical model that accounts for the simultaneous influences of competitive inhibition, time-dependent inactivation and induction of CYP3A in both the liver and intestine in order to provide a net drug-drug interaction prediction in terms of AUC ratio. This model provides a framework by which readily obtained in vitro values for competitive inhibition, time-dependent inactivation and induction for the precipitant compound as well as literature values for fm and FG for the object drug can be used to provide quantitative predictions of DDIs. Using this model, DDIs arising via inactivation (e.g. erythromycin) continue to be well predicted, while those arising via competitive inhibition (e.g. ketoconazole); induction (e.g. phenytoin) and mixed mechanisms (e.g. ritonavir) are also predicted within the ranges reported in the clinic. This comprehensive model quantitatively predicts clinical observations with reasonable accuracy and can be a valuable tool to evaluate candidate drugs and rationalize clinical DDIs.


Key words: CYP induction, CYP inhibition, CYP3A, hepatocytes, human CYP enzymes, in vitro-in vivo prediction, inactivation, induction, liver microsomes, mechanism-based inhibition


This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
O. A. Fahmi, S. Boldt, M. Kish, R. S. Obach, and L. M. Tremaine
PREDICTION OF DRUG-DRUG INTERACTIONS FROM IN VITRO INDUCTION DATA: Application of the Relative Induction Score Approach Using Cryopreserved Human Hepatocytes
Drug Metab. Dispos., September 1, 2008; 36(9): 1971 - 1974.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.